MRX: cheap growth, leverage attached

Marex Group (NASDAQ: MRX) is today's four-filter pass: a London-based capital-markets firm with a $4.61 billion market cap, 32.60% TTM net revenue growth, a 0.64 PEG ratio, and positive FY2025 operating cash flow of $667.5 million. 1 2 3 4

The catch is that MRX is not a simple low-debt compounder. It is a broker, clearing firm, market maker, and commodities platform whose reported leverage looks extreme because its balance sheet includes repos, securities lending, short securities, client balances, and other trading-related liabilities. The stock has already tripled from its April 2024 IPO price near $19 to $64.12, and the average analyst target now sits below the current price. 1 2

Revenue definition matters. Marex reports IFRS revenue on a net basis: net commission income, net trading income, net interest income, and net physical commodities income after direct costs. That is why the useful growth base is the $2.25B TTM net revenue figure, not the $3.27B middle-ground gross figure shown by some data vendors or the $4.10B Finviz sales figure. 6 3 1

Marex Group is a diversified financial-services platform that connects clients to energy, commodities, and financial markets. Its four reporting segments are Clearing, Agency and Execution, Market Making, and Hedging and Investment Solutions. 6

The business is more like StoneX Group (SNEX) or Virtu Financial (VIRT) than a conventional bank. Marex earns economics from clearing, execution, spreads, structured products, financing, and commodities activity rather than from selling a single software or consumer product. That makes revenue quality harder to read from a simple sales line, but it also explains why Q1 2026 surged when commodity and financial-market volatility rose. 6

Marex went public in April 2024 at about $19 per share. By June 25, 2026, the stock closed at $64.12, roughly 3.4 times the IPO price. 1

Q1 2026 was the cleanest reason MRX showed up in the screen. Marex reported record quarterly net revenue of $692.3M, up 48% from $467.3M in Q1 2025, and adjusted profit before tax of $152.7M, up 59% year over year. 6

The growth was broad across the platform. In Q1 2026, Clearing revenue rose 15%, Agency and Execution rose 35%, Market Making rose 164%, and Hedging and Investment Solutions rose 107% year over year. 6

Ian Lowitt, Marex's group CEO, said the quarter was the company's eighth as a public company and that every one had shown year-over-year profit growth. He also said Q1 volatility was not expected to persist at the same intensity, which is the right caution for this stock: the same volatility that made the quarter strong can fade. 6

MRX looks inexpensive on earnings-based multiples, but only if the expected growth rate holds. Finviz reports trailing P/E of 14.82, forward P/E of 11.10, PEG of 0.64, P/S of 1.13, and P/B of 3.62. 1 StockAnalysis reports trailing P/E of 14.68, forward P/E of 12.26, P/S of 1.41, and P/B of 3.68. 2

That peer set gives a mixed answer. MRX is cheaper than StoneX on P/E and EV/EBITDA, but it is not cheaper than Virtu on trailing P/E. The MRX bull case depends less on being the absolute cheapest capital-markets stock and more on the combination of mid-teens earnings multiples, 17.38% expected EPS growth, and a 29% ROE. 1 2

P/FCF is also reasonable on FY2025 free cash flow. Yahoo Finance reports FY2025 free cash flow of $647.7M, implying a market-cap-to-FCF multiple of roughly 7.1x at a $4.61B market cap. 4

The headline debt-to-equity ratio is the main reason MRX cannot be treated like a normal low-leverage growth pick. Finviz reports D/E of 7.68, while StockAnalysis reports 9.74. StockAnalysis also shows total debt of $13.12B against book equity of roughly $1.35B. 1 2

For a capital-markets firm, that ratio needs context. Marex's reported liabilities include repurchase agreements, stock lending, short securities, debt securities, and other trading-related balances that are matched against liquid assets and client-related positions. Marex reported Q1 2026 total assets of $36.53B, total liabilities of $35.18B, and total equity of $1.35B. 6

The capital position looks stronger than the raw D/E ratio implies. Marex reported a total capital ratio of 253% against a regulatory requirement of $402.6M and total available liquid resources of $2.99B at Q1 2026. 6

Cash generation clears the hard screen. Yahoo Finance reports operating cash flow of $667.5M for FY2025 and $1.16B for FY2024, while StockAnalysis reports FY2025 free cash flow of $654.4M and FY2024 free cash flow of $1.15B. 4 10

M&A is adding product breadth. Marex completed its Winterflood acquisition on December 1, 2025; the retained market-making operations are expected to generate about $75M of annual revenue at about a 20% adjusted PBT margin over time, and the WBS custody arm sale to Epiris was expected to close in Q2 2026 with a $40M capital benefit. 11

Webb Traders expands equity derivatives. Marex announced on February 6, 2026 that it would acquire Webb Traders, an Amsterdam- and Paris-based equity derivatives market maker specializing in single-stock options for EU and US mid- and large-cap equities; closing was expected in Q2 or Q3 2026, subject to regulatory approval. 12

Levmet adds European power and gas capability. Marex acquired Levmet on June 1, 2026 to expand European power and gas physical market-making capabilities, according to FX News Group. 13

Digital-market infrastructure is a smaller but visible option. On June 17, 2026, HIFI, DRW, and Marex completed an onchain repo transaction on the Canton Network, with Marex acting as prime broker and the trade executed through Tradeweb's RFQ protocol. 14

The next earnings report is the near-term test. StockAnalysis lists Q2 2026 earnings as expected on August 12, 2026, before market open. 2 That report should show whether Q1's volatility-driven results normalized or whether the platform kept enough trading and client activity to support the full-year setup.

Risk 1: Leverage optics and funding cost. The D/E range of 7.68 to 9.74 is not directly comparable to an industrial company, but it still matters because Marex relies on liquid markets and funding access. Interest expense rose to $86.2M in Q1 2026 from $65.9M in Q1 2025, partly reflecting debt issuance and structured notes. 6 A practical trigger is whether Q2 and Q3 2026 show continued capital-ratio strength above the Q1 2026 level of 253%. 6

Risk 2: Short-seller and lawsuit overhang. NINGI Research published a short-seller report on August 5, 2025, and the research package notes that the full report was inaccessible during collection. Marex also faced securities-law-firm notices beginning in December 2025, but the specific complaint details were not available in the collected materials. 1 This is not enough evidence to accept the bear case, but it is enough to demand tighter monitoring of cash-flow classification, leverage disclosures, and legal updates.

Risk 3: A real client default hit Q1. Marex recorded a $28.2M trading loss and a $5.7M credit-loss provision tied to a natural gas client default in Q1 2026. 6 A one-off default can be absorbed in a record quarter; repeated client losses would change the quality of the earnings story.

Risk 4: Insider selling near the highs. CEO Ian Lowitt sold 37,143 shares at an average price of $62.37 on June 12, 2026, and officer Paolo Tonucci sold 16,666 shares at an average price of $62.45 on June 15, 2026; Tonucci also filed for a proposed sale of 66,666 additional shares. 1 The sales appear to be under Rule 10b5-1 plans, and Lowitt still held 2,831,358 shares after the sale, so this is not an automatic sell signal. It is a watch item because the stock is trading close to the top of its public-market range. 1

Risk 5: Analyst targets are lagging the stock. Eight analysts cover MRX with Buy-equivalent ratings, but StockAnalysis shows an average target of $58.13 while Finviz shows $61.29, both below the $64.12 close. 2 1 TD Cowen raised its target to $75 on June 8, 2026, which is the main recent target above the current price. 15

MRX closed at $64.12 on June 25, 2026, with a 52-week range of $27.91 to $67.35 and a 52-week gain of about 67%. 1 Short interest is moderate rather than extreme: Finviz reports 5.11% of float short, while StockAnalysis reports 5.98%. 1 2

Institutional ownership is high. Finviz reports 73.90%, while StockAnalysis reports 77.96%; Yahoo Finance lists BlackRock, Capital International, and Fidelity-related entities among major holders. 1 2 16

The near-term watchlist is straightforward: Q2 2026 earnings expected August 12, the WBS sale expected to close in Q2 2026, the Webb Traders close expected in Q2 or Q3 2026, and the Bermuda redomiciling expected in H2 2026 after shareholder approval on May 21, 2026. 2 11 12

MRX is Pass #35 for the daily screen: market cap around $4.61B, TTM net revenue growth of 32.60%, PEG of 0.64, and positive FY2025 operating cash flow of $667.5M. 1 2 3 4

The bull case is that Marex has a diversified capital-markets platform, 29% ROE, strong Q1 2026 momentum, and still-reasonable earnings multiples despite a 3.4x move since IPO. The bear case is that the balance sheet is hard to underwrite, the short-seller and legal overhangs are unresolved, insiders are selling near all-time highs, and Q1 benefited from volatility that management itself does not expect to persist at the same level. 1 6

For investors using this screen as a watchlist tool, the follow-up research question is narrow: does the August Q2 report show durable net revenue growth after Q1 volatility cools, while capital ratios and client-risk losses stay controlled?